KICIAK, Adam (ul. Bohaterów Września 3/83, Warszawa, PL-02-389, PL)
MICHAŁOWSKI, Paweł (ul. Lipowa 9, Michałów Grabina, PL-05-126, PL)
KICIAK, Adam (ul. Bohaterów Września 3/83, Warszawa, PL-02-389, PL)
| Claims 1 . Use of a mixture live cultures probiotic bacteria in a mixture with short chained fatty acids (SCFA), in a slow release form for the active ingredients, of various release structures and mechanisms, in particular in the form of a triglyceride matrix; in the diet of monogastric animals, in particular a human diet, for modulating intestinal bacterial flora as well as improving the acid-base and water-electrolyte balance of the the gastrointestinal tract; in the manufacturing of a preparation for maintaining bacterial and acid-base homeostasis of the distal portion of the gastrointestinal tract of monogastric animals, including the human small intestine and colon. 2. The use of a mixture of probiotic bacteria with protected short chained fatty acids and/or salts thereof selected from among fumaric acid, citric acid, malic acid, sorbic acid and sodium butyrate in the manufacturing of a preparation for maintaining bacterial and acid-base homeostasis of the distal portion of the gastrointestinal tract of monogastric animals, including the human small intestine and colon. 3. A use according to Claim 1 or 2, characterised in that in the manufacturing of the preparation, additional use is made of selected probiotic bacteria with defined functions, as well as active ingredients that affect the pH stability of the distal portion of the gastrointestinal tract, which exhibit bactericidal and bacteriostatic activity against pathogenic and facultatively pathogenic bacteria, that affect the the state of intestinal mucosa and, by the same token, the proliferation and settlement of the intestinal wall by probiotic bacteria. 4. A use according to Claim 1 or 2, characterised in that the preparation produced contains a mixture of live, selected probiotic bacteria: Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at 1 x 109 CFU/g; fumaric acid in the amount of 100 mg/g, citric acid in the amount of 60 mg/g, malic acid in the amount of 40 mg/g, sorbic acid in the amount of 50 mg/g, triglyceride matrix in the amount of 250 mg/g as well as ancillary substances up to 1 g. 5. A use according to Claim 1 or 2, characterised in that the preparation produced is in the form of hard cellulose or gelatine capsules with a net weight of 500 mg. 6. A preparation that facilitates the restoration of an appropriate microbiological equilibrium as well as regulating the pH of intestinal contents, and which concurrently nourishes the cells of the intestinal mucosa, which ensures the proper functioning of the distal portion of the gastrointestinal tract, maintains the microbiolgical and acid-base equilibrium of the gastrointestinal tract characterised in that it contains live bacteria: Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus, as well as fumaric acid, citric acid, malic acid, and sorbic acid in a triglyceride matrix. 7. A preparation according to Claim 6 characterised in that it contains Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at 2 x 109 CFU/g, fumaric acid in the amount of 100 mg/g, citric acid in the amount of 60 mg/g, malic acid in the amount of 40 mg/g, sorbic acid in the amount of 50 mg/g, triglyceride matrix in the amount of 250 mg/g and ancillary substances. 8. A preparation according to Claim 7 characterised in that is in the form of hard cellulose or gelatine capsules with a mass of 500 mg. 9. The use of a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as short-chained fatty acids protected in a triglyceride matrix that slowly releases the active ingredients contained therein into the gastrointestinal tract, in the feeding of monogastric animals for the modulation of: bacterial flora, the pH of intestinal contents and water balance. 10. The use of a preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, preferentially, a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at a total density of 2 to 4 x 109 CFU, fumaric acid in the amount of 100 to 150 mg/g and/or 60 to 120 mg/g and/or malic acid in the amount of 40 to 80 mg/g, and/or sorbic acid in the amount of 50 to 100 mg/g and a triglyceride matrix in the amount of 200 - 300 mg/g as well as ancillary substances up to 1 g, particularly a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at a density of 2 x 109 CFU/g, fumaric acid in the amount of 100 mg/g, and citric acid in the amount of 60 mg/g, and malic acid in the amount of 40 mg/g, and sorbic acid in the amount of 50 mg/g, triglyceride matrix in the amount of 250 mg as well as ancillary substances to 1 g. 1 1 . A preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, according to Claims 5 or 8, which is post prandially administered orally, divided into doses. 12. A preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, according to Claims 5 or 8, which is administered orally as a supplement in humans in order to maintain bacterial and acid-base homeostasis the gastrointestinal tract, including the barrier function of the distal portion of the gastrointestinal tract against bacteria and fungi introduced with food. 13. A preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, according to Claims 5 or 8, which is administered orally, in particular in persons who acutely or chronically take preparations that affect the pH of the distal portion of the gastrointestinal tract. 14. A preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, according to Claims 5 or 8, which is administered prophylactically in persons who have moved to a new climatic zone, in particular a tropical and subtropical zone. 15. A preparation for maintaining bacterial and acid-base homeostasis the gastrointestinal tract of monogastric organisms, including humans, characterised in that contains live, selected bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus, as well as a mixture of acids: fumaric acid, citric acid, D,L-malic acid and sorbic acid in a triglyceride matrix as well as ancillary substances. 16. A preparation according to Claim 15 characterised in that contains live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at 2 x 109 CFU/g, fumaric acid w i/osci 100 mg/g, citric acid in the amount of 60 mg/g, malic acid in the amount of 40 mg/g, sorbic acid in the amount of 50 mg/g, triglyceride matrix in the amount of 250 mg/g and ancillary substances to 1 g. 17. A preparation according to Claims 5 or 8, characterised in that it is meant for prophylactic oral administration in doses of 500 mg to 1000 mg thrice daily, preferentially, during meals. 18. A preparation according to Claims 5 or 8 characterised in that 1 - 2 capsule thrice daily are used post prandum. 19. A use according to Claims 1 or 2, characterised in that in the manufacturing of the preparation additionally makes use of selected cultures of probiotic bacteria that affect the pH of the distal portion of the gastrointestinal tract, in particular increasing the immunity and resistance of the host organism. 20. A use according to Claims 1 or 2, characterised in that in the manufacturing of the preparation additionally makes use of active ingredients that affect the intestinal pH, particularly ones that constitute an energy source for cells of the intestinal mucosa. 21 . A use according to Claims 1 or 2, characterised in that in the manufacturing of the preparation additionally makes use of active ingredients that affect the intestinal pH, particularly ones that accelerate the regeneration of the cells of the intestinal mucosa. 22. A use according to Claims 1 or 2, characterised in that in the manufacturing of the preparation additionally makes use of active ingredients that affect the bacterial flora of the small intestine and colon, particularly ones that restore the proper functioning of the intestines. |
Some disruptions in the functioning of the gastrointestinal tract, including those caused by dietary changes, are made evident by diarrhea and/or increased gas production (ammonia, hydrogen sulphide and derivatives), which causes distention, abdominal discomfort and pain of varying intensity. These are usually based on acid-base disequilibria in the individual sections of the gastrointestinal tract, which damages the gastrointestinal epithelium and shifts the intestinal bacterial flora towards pathogenic and/or facultatively pathogenic species.
Deleterious pH shifts in the gastrointestinal lumen are usually directly connected with disruptions of the integrity of the gastric and intestinal mucosa. The ability of the stomach, duodenum and the entire lower gastrointestinal tract to remain undamaged in an environment containing digestive juices as well as the capability of reacting to damage is dependent on physiological equilibrium between aggressive factors in the gastrointestinal lumen and defensive and regenerative mechanisms of the mucosa. Mucous membrane defensive factors include: carbonate and mucus secretion, prostaglandin production, epithelial hydrophobicity ensured by mucus proteins, as well as maintaining adequate blood flow in the mucous membrane. Regenerative mechanisms consist of repair, regeneration and typical healing processes. Conditional to the activation of these mechanisms is the maintenance of the basal membrane of the epithelium. When this is damaged, the disease develops and clinical symptoms appear. Similar changes occur following antibiotic, chemo- and radiotherapy, during which the mucosa are damaged or destroyed and the bacterial equilibrium is disrupted. Reinstitution of the healthy structure of mucosal cells, as well as the proper composition and density of bacterial flora is essential to convalescence and healing.
To date, there are no preparations composed of a mixture of live bacterial cultures with organic acids and/or salts thereof, which would be capable of significantly affecting the maintenance and modification of proper bacterial flora and pH of the lower gastrointestinal tract. For this purpose, it was common to use probiotics containing mixtures of various strains, mainly LAB. However, the chronic use of these often exerts a negative impact on the composition and functioning of the bacterial flora of the gastrointestinal tract. The activity of probiotic preparations is dependent on whether, and what kind of medicinal products are taken in parallel with them.
The subject of the present invention is the use of a mixture of probiotic bacteria in a mixture with short chain fatty acids (SCFA), in a form that slowly releases active substances with varying structure and release mechanisms, in the diet of monogastric animals, in particular the human diet, in order to modulate intestinal bacterial flora and to improve the acid-base and water-electrolyte management of the gastrointestinal tract, in the manufacturing a preparation for maintaining the bacterial and acid-base bacterial and acid-base homeostasis of the distal portion of the gastrointestinal tract of monogastric animals, includng the human small intestine and colon.
Use of a mixture of probiotic bacteria with protected short chain fatty acids and/or salts thereof selected from among fumaric acid, citric acid, malic acid, sorbic acid and sodium butyrate in the manufacturing of a preparation for maintaining the bacterial and acid- base homeostasis of the distal portion of the gastrointestinal tract of monogastric animals, including the human small intestine and colon.
Preferentially, the use according to the present invention is characterised in that in the manufacturing of the preparation use is additionally made of live bacterial cultures selected from among probiotic bacteria of particular function as well as active ingredients that affect the stability of the pH of the distal portion of the gastrointestinal tract, that exhibit bacteriocidal properties against pathogenic and facultatively pathogenic bacteria, and affect the intestinal mucosa and, by the same token, the proliferation and settlement of probiotic bacteria on intestinal walls.
Equally preferentially, the use according to the present invention is characterised in that preparation produced contains a mixture of live, selected probiotic bacteria: Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at 1 x 10 9 CFU/g, fumaric acid in the amount of 100 mg/g, citric acid in the amount of 60 mg/g, malic acid in the amount of 40 mg/g, sorbic acid in the amount of 50 mg/g, triglyceride matrix in the amount of 250 mg/g as well as ancillary substances to 1 g. A preferential use according to the present invention is characterised in that the preparation produced is in the form of hard cellulose or gelatine capsules with a net weight of 500 mg.
Another solution according to the present invention is a preparation which makes it possible to restore proper microbiological equilibrium as well as regulating the pH of intestinal contents, with the concurrent nourishment of intestinal mucosal cells, which ensures the proper functioning of the distal portions of the gastrointestinal tract, maintains the microbiological and acid-base equilibrium of the gastrointestinal tract, characterised in that contains live bacteria: Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus, as well as fumaric acid, citric acid, malic acid, and sorbic acid in a triglyceride matrix.
Preferentially, a preparation according to the present invention is characterised in that it contains Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at 2 x 10 9 CFU/g, fumaric acid in the amount of 100 mg/g, citric acid in the amount of 60 mg/g, malic acid in the amount of 40 mg/g, sorbic acid in the amount of 50 mg/g, triglyceride matrix in the amount of 250 mg/g and ancillary substances.
Preferentially, a preparation according to the present invention is characterised in that it is in the form of hard cellulose or gelatine capsules weighing 500 mg .
According to another embodiment the present invention relates to the use of a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus and short chained fatty acids in a form slowly released in the human intestines, in a diet for humans in order to modulate bacterial flora, to and to modulate the pH of intestinal contents and water balance.
According to the first alternate embodiment, the present invention relates to the use of a mixture of live bacterial cultures of Lactobacilfus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as short-chained fatty acids protected in the triglyceride matrix that slowly releases the active ingredients contained therein into the gastrointestinal tract, in the nutrition of mono-gastric animals in order to modulate bacterial flora, the pH of gastrointestinal contents and water balance.
According to a second alternate embodiment, the present invention relates to the use of a preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, preferentially, a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at a total density of 2 to 4 x 10 9 CFU, fumaric acid in the amount of 100 to 150 mg/g and/or citric acid in the amount of 60 to 120 mg/g and/or malic acid in the amount of 40 to 80 mg/g, and/or sorbic acid in the amount of 50 to 1 00 mg/g and triglyceride matrix in the amount of 200 - 300 mg/g as well as ancillary substances up to 1 g, particularly a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at a density of 2 x 10 9 CFU/g fumaric acid in the amount of 100 mg/g, and citric acid in the amount of 60 mg/g, and malic acid in the amount of 40 mg/g, and sorbic acid in the amount of 50 mg/g, triglyceride matrix in the amount of 250 mg as well as ancillary substances to 1 g.
It is also preferable when a preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, is administered orally divided into doses, following a meal.
It is also preferable when a preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, is administered orally as a supporting treatment in humans to maintain the bacterial and acid-base homeostasis the gastrointestinal tract, including the barrier function of the distal portion of the gastrointestinal tract against bacteria and fungi introduced along with food.
It is also preferable when a preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, is administered orally, in particular in persons acutely or chronically taking preparations that affect the pH of the distal portion of the gastrointestinal tract.
It is also preferable when a preparation containing a mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus , as well as fumaric acid and/or citric acid and/or malic acid and/or sorbic acid in a triglyceride matrix, is administered prophylactically in persons, who have moved to a different climate zone, in particular a tropical or sub-tropical zone.
It is preferable when the above product is packed into hard cellulose capsules, with a net weight of 500 mg.
It is preferable when the above product is used following a meal at a rate of 1 - 2 capsules thrice daily.
It is preferable when select cultures of probiotic bacteria are used in the manufacturing of the preparation, which affect the pH of the distal portion of the gastrointestinal tract, particularly those that increase immunity and resistance of the host organism, as well as when the manufacturing of such a preparation additionally makes use of active ingredients that affect intestinal pH, particularly those that constitute an important energy source for intestinal mucosal cells, as well as if the manufacturing additionally makes use of active ingredients that affect intestinal pH, particularly those that accelerate the regeneration of intestinal mucosal cells, as well as if the manufacturing of such a preparation additionally makes use of active ingredients that affect the bacterial flora of the small intestine and colon, particularly those that restore the proper intestinal function.
According to the present invention, such use facilitates the restoration and maintenance of bacterial and acid-base homeostasis of the distal portion of the gastrointestinal tract. A mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus and short-chained fatty acids or their salts in a triglyceride matrix (a form in which they significantly affect the development of probiotic bacteria), at the same time acting as a bactericide towards pathogenic and facultatively pathogenic bacteria, improving the condition of intestinal mucosal cells, facilitates the maintenance of the proper microbiological equilibrium of the gastrointestinal tract, at the same time affecting the maintenance of the acid-base equilibrium.
A significant feature of the present invention is the simultaneous use of live cultures of probiotic bacteria and protected short-chained fatty acids, the use of the unexpected synergism of live bacterial cultures and protected fatty acids, which increased the activity of such a mixture to an unexpected degree in relation to its each individual component. Unexpectedly, it turned out possible to use a mixture live bacterial cultures of and protected short-chained fatty acids or their salts, which in this form modify the pH of gastrointestinal contents while simultaneously modulating the bacterial flora and improving (normalising) the water balance to restore the bacterial and acid-base homeostasis the gastrointestinal tract,
Unexpectedly, it also turned out to compose such a composition of mixture live bacterial cultures with SCFA of natural origin and such a mixture of bacterial cultures of a predefined density as well as such mutual interrelationships between them and doses of protected fatty acids, which after the application of active ingredient release control techniques can significantly affect the settlement and proliferation of probiotic bacteria (introduced and already extant in the gastrointestinal tract), attainment of the correct pH of instestinal contents as well as making use of their bectericidal and bacteriostatic properties and which also supplies energy to cells of the intestinal mucosa.
One of the conditions for the safe use of the product was the selection of SCFA occurring in natural as well as appropriately selected bacterial strains.
The matrix was composed such that the release period of the substances contained therein was equal to the average total passage time of nutrients through the gastrointestinal tract of a healthy human.
Unexpectedly, it turned out, ze the mixture of live bacterial cultures of Lactobacillus rhamnosus GG, Bifdobacterium and Streptococcus thermophilus and short chain fatty acids in form slowly released in the human gastrointestinal tract, including those protected in a triglyceride matrix, according to the present invention, may be used in human and monogastric animal nutrition.
Example embodiment of the present invention.
Manufacturing of the product for use in humans, containing z live cultures of
Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus, as well as fumaric acid, citric acid, malic acid, sorbic acid in a triglyceride matrix, in cellulose or gelatine capsules. In a homogenizer, Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus supplemented with ancillary substances are mixed to obtain the rquired product consistency. After homogenization, the product is packed into containers specially prepared for this purpose, from which samples are taken for analysis.
The powder thus produced, containing live bacterial cultures and meeting quality requirements, together with a separately produced microgranulate containing normalized quantities of fumaric acid, citric acid, D-L-malic acid and sorbic acid in a triglyceride matrix, is then sent for encapsulation in two sections of the same encapsulating machine. The first section loads the capsule with a predefined quantity of powder of a particular microbiological density, whereas the second section (adapted for pellets and granulates) tops up the capsule with an appropriate quantity of microgranulate containing protected organic acids. Thusly filled capsules are then sent for analysis, and then (depending on the size of packaging) packaged in blisters and placed in carton units or packaged in PE containers.
Examples
In the experiment we used 12 pigs of the Polish White breed (Local Ethics Committee permit application No. 25/2002, Opinion No. 24/2002, 26.06.2002) weaned on the 28th day of life and maintained for 6 days on a commercial adaptation starter diet fed ad libitum. Next, each pig was given an intramuscular injection of Ijpopolysaccharide (LPS from Escherichia co// ' 026:B6, Sigma, St. Louis, Missouri) at a rate of 150 mg/kg body mass. The LPS was diluted in physiological saline at a concentration of 1 .5 mg/ml. Over a period of < 12 hours, clinical symptoms of diarrhea were noted in all of the animals. Next, the pigs were divided into three equal groups:
A - the pigs were given a preparation in cellulose capsules, which had the following composition: live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at 1 x 1 0 9 CFU/g, fumaric acid in the amount of 100 mg/g, citric acid in the amount of 60 mg/g, malic acid in the amount of 40 mg/g, sorbic acid in the amount of 50 mg/g, as well as typical ancillary substances to 1 g, embedded in a triglyceride matrix (250 mg/g), at a dose of 2x1 capsules daily.
B - the pigs were given a preparation in cellulose capsules, which had the following composition: live bacterial cultures of Lactobacillus rhamnosus GG, Bifidobacterium and Streptococcus thermophilus at 1 x 10 9 CFU/g as well as typical ancillary substances to 1 g, at a dose of 2x1 capsules daily.
C - the pigs were given a preparation in cellulose capsules, which had the following composition: typical ancillary substances, at a dose of 2x1 capsules daily.
At the same time, in all groups, we continued the administration of commercial feed. In all of the animals of group A, we observed the remission of all signs of diarrhea in < 48 hours. Similar effects were not observed in any of the animals of groups B and C. After 48 hours, in animals from groups B and C we initiated additional, typical veterinary procedures required for the treatment of diarrhea.
Next Patent: PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS